Oral Nano Drug Delivery Systems for the Treatment of Type 2 Diabetes Mellitus: An Available Administration Strategy for Antidiabetic Phytocompounds

• Published in: International journal of nanomedicine Vol. 15; pp. 10215 - 10240
• Main Authors: Nie, Xin, Chen, Zhejie, Pang, Lan, Wang, Lin, Jiang, Huajuan, Chen, Yi, Zhang, Zhen, Fu, Chaomei, Ren, Bo, Zhang, Jinming
• Format: Journal Article
• Language: English
• Published: New Zealand Taylor & Francis Ltd 01.01.2020; Dove; Dove Medical Press
• Subjects: Administration, Oral; antidiabetic effects; Antidiabetics; Carbohydrates; Diabetes; Diabetes Mellitus, Type 2 - drug therapy; Drug Carriers - chemistry; Drug delivery systems; Drug dosages; Enzymes; FDA approval; Flavonoids; Glucose; Herbal medicine; Humans; Hyperglycemia; Hypoglycemic Agents - administration & dosage; Hypoglycemic Agents - pharmacology; Hypoglycemic Agents - therapeutic use; Insulin resistance; Kinases; nanoparticles (nps); Nanoparticles - chemistry; Needlestick injuries; Oral administration; Patient compliance; Phytochemicals - administration & dosage; Phytochemicals - pharmacology; Phytochemicals - therapeutic use; phytocompounds; Polyphenols; Proteins; Review; type 2 diabetes mellitus (t2dm); drug delivery systems; phytocompounds; nanoparticles (NPs); antidiabetic effects; type 2 diabetes mellitus (T2DM)
• ISSN: 1178-2013; 1176-9114; 1178-2013
• DOI: 10.2147/IJN.S285134

In view of the worldwide serious health threat of type 2 diabetes mellitus (T2DM), natural sources of chemotherapies have been corroborated as the promising alternatives, with the excellent antidiabetic activities, bio-safety, and more cost-effective properties. However, their clinical application is somewhat limited, because of the poor solubility, instability in the gastrointestinal tract (GIT), low bioavailability, and so on. Nowadays, to develop nanoscaled systems has become a prominent strategy to improve the drug delivery of phytochemicals. In this review, we primarily summarized the intervention mechanisms of phytocompounds against T2DM and presented the recent advances in various nanosystems of antidiabetic phytocompounds. Selected nanosystems were grouped depending on their classification and structures, including polymeric NPs, lipid-based nanosystems, vesicular systems, inorganic nanocarriers, and so on. Based on this review, the state-of-the-art nanosystems for phytocompounds in T2DM treatment have been presented, suggesting the preponderance and potential of nanotechnologies.